As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.
11 Analysts have issued a CARGO Therapeutics forecast:
11 Analysts have issued a CARGO Therapeutics forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -147 -147 |
3%
3%
|
EBIT (Operating Income) EBIT | -155 -155 |
1%
1%
|
Net Profit | -222 -222 |
50%
50%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.
Head office | United States |
CEO | Anup Radhakrishnan |
Employees | 167 |
Founded | 2019 |
Website | cargo-tx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.